Background: Anovulation is the most common cause for infertility, different oral agents are used for induction of ovulation, tamoxifen may be effective as letrozole in this era. Objective: The aim of this study was to compare the effectiveness of tamoxifen and letrozole in terms of ovulation induction outcomes in non PCOS anovulatory patients. Patients and Methods: This randomized single blinded clinical trial was conducted among a total of 120 patients with anovulatory infertility that were randomized to one of two treatment arms: Letrozole group and Tamoxifen group. The treatment was continued for three consecutive cycles. Main outcome measures were number of follicles ≥ 18mm, endometrial thickness and ovulation rate. Secondary outcomes measures were cumulative pregnancy rate and spontaneous abortion rates. Results: Mean number of mature of follicles ≥ 18 mm was statistically significantly higher in Tamoxifen group (1.9 ± 1.1) when compared to Letrozole group (1.5 ± 0.9) with p-value=0.03. Also, endometrial thickness was significantly different between both groups; as it was higher in Tamoxifen group (8.2 ± 1.6 mm versus 7.08 ± 2.4 mm) in Letrozole group (p-value=0.02). No significant difference was reported between both groups as regarding ovulation rate, pregnancy rate and spontaneous abortion rate, ovulation rate was 73.3% with Letrozole and 63.3% with Tamoxifen (P =0.3), cumulative pregnancy rate was 30% with Letrozole group and 23.3% with Tamoxifen group (p=0.5) and spontaneous abortion rate was 3.3% in Letrozole group and 5% in Tamoxifen group (p=0.9). Conclusion: Tamoxifen drug has comparable ovulation induction outcomes to letrozole with very low costs and side effects. Tamoxifen could be considered suitable for ovulation induction in developing countries
Kishk, E. (2019). Letrozole versus tamoxifen for ovulation induction in non-polycystic ovarian syndrome anovulatory infertile females. Evidence Based Women's Health Journal, 9(2), 468-473. doi: 10.21608/ebwhj.2019.33487
MLA
Eman Ahmed Kishk. "Letrozole versus tamoxifen for ovulation induction in non-polycystic ovarian syndrome anovulatory infertile females". Evidence Based Women's Health Journal, 9, 2, 2019, 468-473. doi: 10.21608/ebwhj.2019.33487
HARVARD
Kishk, E. (2019). 'Letrozole versus tamoxifen for ovulation induction in non-polycystic ovarian syndrome anovulatory infertile females', Evidence Based Women's Health Journal, 9(2), pp. 468-473. doi: 10.21608/ebwhj.2019.33487
VANCOUVER
Kishk, E. Letrozole versus tamoxifen for ovulation induction in non-polycystic ovarian syndrome anovulatory infertile females. Evidence Based Women's Health Journal, 2019; 9(2): 468-473. doi: 10.21608/ebwhj.2019.33487